Frusecare 40 mg Tablets

Maa: Yhdistynyt kuningaskunta

Kieli: englanti

Lähde: VMD (Veterinary Medicines Directorate)

Osta se nyt

Valmisteyhteenveto Valmisteyhteenveto (SPC)
20-07-2021

Aktiivinen ainesosa:

Furosemide

Saatavilla:

Dechra Limited

ATC-koodi:

QC03CA01

INN (Kansainvälinen yleisnimi):

Furosemide

Lääkemuoto:

Tablet

Prescription tyyppi:

POM-V - Prescription Only Medicine – Veterinarian

Terapeuttinen ryhmä:

Cats, Dogs

Terapeuttinen alue:

Cardio Vascular diuretic

Valtuutuksen tilan:

Expired

Valtuutus päivämäärä:

1999-05-13

Valmisteyhteenveto

                                Revised: November 2016
AN: 01006/2016
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Frusecare 40 mg Tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 40 mg Frusemide (Furosemide).
For a full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Tablets.
White, circular, biconvex, flat-faced tablets with bevelled edges and
a breakline.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Cats and dogs.
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the treatment of oedema associated with cardiac insufficiency,
renal dysfunction and
trauma in cats and dogs.
In animals with pulmonary oedema of cardiac origin, combined therapy
with other medicinal
products may be indicated.
4.3
CONTRAINDICATIONS
Do not use in animals with acute glomerular nephritis, renal failure
with anuria, electrolyte
deficiency disease or in animals that have received an overdosage of
digitalis.
Do not use concurrently with aminoglycoside antibiotics.
Do not use in animals weighing less than 4 kg.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
There are no special warnings required for either target species.
4.5
SPECIAL PRECAUTIONS FOR USE
i. Special precautions for use in animals
Do not exceed the recommended dosage.
Therapeutic efficacy may be impaired by increased intake of drinking
water. Where the
animal’s condition permits, water intake should be restricted during
treatment.
Revised: November 2016
AN: 01006/2016
Monitoring of plasma potassium levels is advisable during periods of
prolonged treatment of
combined therapy with cardiac glycosides. Potassium supplements may be
necessary.
ii. Special precautions to be taken by the person administering the
veterinary medicinal
product to animals
Wear gloves, or wash your hands immediately after handling the
tablets.
iii. Other precautions
None.
4.6
ADVERSE REACTIONS (FREQUENCY AND SERIOUSNESS)
Administration at the recommended dosage level is not normally
associated with
undesirable effects.
4.7
USE DURING PREGNANCY, LACTATION OR LAY

                                
                                Lue koko asiakirja
                                
                            

Etsi tähän tuotteeseen liittyviä ilmoituksia